ON 01910.Na

DRUG9 trials

Conditions

Acute Lymphocytic LeukemiaAcute Myelocytic LeukemiaAcute Myeloid LeukemiaChronic Lymphocytic LeukemiaChronic Myelocytic LeukemiaChronic Myelomonocytic LeukemiaMDSMalignant Neoplasmas

Phase 1

Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)

CompletedNCT00854646

Traws Pharma, Inc.Acute Lymphocytic Leukemia, Acute Myelocytic Leukemia, Chronic Lymphocytic Leukemia +2

Start: 2008-10-31End: 2015-12-31Updated: 2018-01-10

Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML

CompletedNCT00854945

Traws Pharma, Inc.Acute Myeloid Leukemia, Myelodysplastic Syndrome

Start: 2009-01-31End: 2014-02-28Updated: 2017-06-26

Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome

CompletedNCT01048619

Traws Pharma, Inc.Myelodysplastic Syndrome

Start: 2009-12-31End: 2015-12-31Updated: 2017-06-23

Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors

CompletedNCT01125891

Traws Pharma, Inc.Malignant Neoplasmas, Solid Tumors

Start: 2009-01-31End: 2011-09-30Updated: 2017-06-23

Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors

CompletedNCT01165905

Traws Pharma, Inc.Solid Tumor

Start: 2010-01-31End: 2011-07-31Updated: 2017-06-23

Phase 2

Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients

CompletedNCT00856791

Traws Pharma, Inc.Ovarian Cancer

Start: 2009-03-31End: 2011-07-31Updated: 2017-07-21

Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk

CompletedNCT00906334

Traws Pharma, Inc.Myelodysplastic Syndrome

Start: 2009-05-31End: 2013-11-30Updated: 2017-06-26

Phase 3

Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts

CompletedNCT01241500

Traws Pharma, Inc.Chronic Myelomonocytic Leukemia, MDS, Myelodysplastic Syndromes +1

Start: 2010-11-30End: 2018-10-03Updated: 2020-06-30

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

CompletedNCT01360853

Traws Pharma, Inc.Metastatic Pancreatic Adenocarcinoma

Start: 2011-05-31End: 2015-12-31Updated: 2016-08-04

Blood2018-11-293 citations

A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.

2017-11-1132 citations

Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.

2016-03-09128 citations

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

Journal of Clinical Oncology2015-05-2010 citations

Overall survival (OS) and baseline disease characteristics in MDS patients with primary HMA failure in a randomized, controlled, phase III study of rigosertib.

Journal of Clinical Oncology2015-05-201 citations

Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients.